X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.prnewswire.com/news-releases/sentynl-therapeutics-receives-mhra-authorization-of-nulibry-fosdenopterin-for-treatment-of-mocd-type-a-in-great-britain-302117194.html
https://www.prnewswire.com/news-releases/sentynl-therapeutics-announces-presentation-of-study-evaluating-the-efficacy-and-safety-of-nulibry-fosdenopterin-for-the-treatment-of-mocd-type-a-at-2023-ssiem-annual-symposium-301920794.html
https://www.pharmacompass.com/pdf/news/comharsas-nulibry-fosdenopterin-receives-approval-in-europe-28956.pdf
https://www.globenewswire.com/news-release/2022/09/20/2519096/0/en/BridgeBio-Pharma-and-Sentynl-Therapeutics-Receive-Marketing-Authorization-in-the-EU-for-NULIBRY-fosdenopterin-for-the-Treatment-of-MoCD-Type-A.html
https://www.globenewswire.com/news-release/2022/08/10/2495664/0/en/BridgeBio-Pharma-Sentynl-Therapeutics-and-Medison-Pharma-Announce-Approval-in-Israel-for-NULIBRY-fosdenopterin-for-the-Treatment-of-MoCD-Type-A.html
https://www.prnewswire.com/news-releases/bridgebio-pharma-and-sentynl-therapeutics-receive-positive-chmp-opinion-for-nulibry-fosdenopterin-for-the-treatment-of-mocd-type-a-301592171.html
http://www.pharmatimes.com/news/fda_approves_nulibry_to_treat_molybdenum_cofactor_deficiency_type_a_1364326
https://endpts.com/bridgebio-spins-gold-out-of-an-alexion-castoff-scoring-an-fda-approval-in-rare-metabolism-disorder/
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-molybdenum-cofactor-deficiency-type
https://www.prnewswire.com/news-releases/fda-approves-first-treatment-for-molybdenum-cofactor-deficiency-type-a-301236745.html
Market Place
Share 
